Aptose Biosciences (TSE:APS) Share Price Crosses Below 50 Day Moving Average – Time to Sell?
by Sarita Garza · The Markets DailyAptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO)’s stock price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$2.20 and traded as low as C$2.12. Aptose Biosciences shares last traded at C$2.12, with a volume of 100 shares traded.
Analyst Ratings Changes
Separately, Alliance Global Partners cut shares of Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Aptose Biosciences presently has an average rating of “Hold”.
Read Our Latest Research Report on Aptose Biosciences
Aptose Biosciences Stock Performance
The business has a 50-day simple moving average of C$2.20 and a 200 day simple moving average of C$2.00. The company has a debt-to-equity ratio of -97.77, a current ratio of 0.53 and a quick ratio of 5.41. The firm has a market cap of C$5.41 million, a PE ratio of 3.07 and a beta of -1.19.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.